Search Results
Dr. Goy Discusses Long-Term Follow-Up Results for Ibrutinib in MCL
Dr. Goy Discusses Single-Agent Ibrutinib in MCL
Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL
Dr. Goy Discusses Ibrutinib With Venetoclax in MCL
Long-Term Results of Ibrutinib/Umbralisib Show Efficacy in CLL and MCL
Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCL
Acalabrutinib monotherapy in R/R MCL: extended follow-up results
Dr. Goy Compares Acalabrutinib With Ibrutinib in MCL
Long-term follow-up of acalabrutinib in R/R mantle cell lymphoma
Real-world results in the UK for ibrutinib at first relapsed for MCL
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
Dr. Goy Discusses BTK Inhibitors in MCL
